ClinicalTrials.gov
ClinicalTrials.gov Menu

Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01622582
Recruitment Status : Completed
First Posted : June 19, 2012
Last Update Posted : March 3, 2015
Sponsor:
Information provided by (Responsible Party):
University of Arkansas

Brief Summary:
Engraftment Syndrome after Autologous Stem Cell Transplant: Retrospective Review in Patients with Multiple Myeloma

Condition or disease
Multiple Myeloma

Detailed Description:
A retrospective chart review series will be performed fpr subjects enrolled from 1/1/2006.

Study Type : Observational
Actual Enrollment : 796 participants
Time Perspective: Retrospective
Official Title: Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma
Study Start Date : January 2006
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources




Primary Outcome Measures :
  1. number of patients developing Engraftment syndrome following stem cell transplant [ Time Frame: 6 months post-transplant ]
    A retrospective review where subjects medical records are studied for development of engraftment syndrome 6 months after stem cell transplant



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Multiple Myeloma, developing engraftment syndrome
Criteria

Inclusion Criteria:

  • Patients with Multiple Myeloma, developing engraftment syndrome

Exclusion Criteria:

  • Patients with Multiple Myeloma, with no features of engraftment syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01622582


Locations
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Investigators
Principal Investigator: Senu Apewokin, MD UAMS

Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT01622582     History of Changes
Other Study ID Numbers: UARK 2008-30
First Posted: June 19, 2012    Key Record Dates
Last Update Posted: March 3, 2015
Last Verified: March 2015

Keywords provided by University of Arkansas:
Multiple Myeloma, Engraftment syndrome

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases